- Medical Director
Mark Kirkland is Associate Professor at the Institute of Technology, Research and Innovation at Deakin University.
He is a specialist Haematologist with more than 25 years research experience in the field of haemopoietic stem cell biology and 15 years experience as a clinical and laboratory haematologist.
A former Medical Director of Research for the Australian Red Cross Blood Service in Victoria, he has extensive experience in tissue banking, both public and private cord blood banking, and bone banking.
He was also a member of the committee that developed the Australian (NPAAC) Guidelines for Haemopoietic Stem Cells.
He is the Chief Scientific Officer of Cytomatrix Pty Ltd, a biotechnology company specialising in novel technologies for the growth and expansion of human adult stem cells.
current research interests include:
Cord blood stem cell expansion
Stem cell reprogramming, with particular emphasis on developing novel approaches to the production of insulin-producing cells and cardiac cells from cord blood stem cells, for the treatment of diabetes and heart disease, respectively, and on reprogramming to pluripotency ("iPS cells")
The clinical use of cord blood in the treatment of cerebral palsy and type 1 diabetes.
has been instrumental in the design and development of Cell Care's
Clinical Trial program, and in particular has instigated the proposed Australia-wide trial in the use of cord blood to prevent the progression of type 1 diabetes.